231 related articles for article (PubMed ID: 8546422)
41. [Abnormal movements of the larynx. Diagnostic approach and therapeutic perspectives].
Angelard B; Feve A; Moine A; Fichaux P; Guillard A; Lacau St Guily J
Ann Otolaryngol Chir Cervicofac; 1993; 110(3):125-8. PubMed ID: 8239331
[TBL] [Abstract][Full Text] [Related]
42. [Effect of cricothyroid and thyroarytenoid muscle botulinum toxin injection on patients with dyspnea caused by bilateral recurrent laryngeal nerve paresis].
Xu XL; Lai JM; Qiu T; Ma YL; Jiao YC; Zhuang PY
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2018 May; 53(5):375-380. PubMed ID: 29764020
[No Abstract] [Full Text] [Related]
43. Effects of botulinum toxin injections on speech in adductor spasmodic dysphonia.
Ludlow CL; Naunton RF; Sedory SE; Schulz GM; Hallett M
Neurology; 1988 Aug; 38(8):1220-5. PubMed ID: 3399071
[TBL] [Abstract][Full Text] [Related]
44. Effects of botulinum toxin type A injections on aerodynamic measures of spasmodic dysphonia.
Adams SG; Durkin LC; Irish JC; Wong DL; Hunt EJ
Laryngoscope; 1996 Mar; 106(3 Pt 1):296-300. PubMed ID: 8614192
[TBL] [Abstract][Full Text] [Related]
45. Measurement of laryngeal resistance in the evaluation of botulinum toxin injection for treatment of focal laryngeal dystonia.
Witsell DL; Weissler MC; Donovan MK; Howard JF; Martinkosky SJ
Laryngoscope; 1994 Jan; 104(1 Pt 1):8-11. PubMed ID: 8295461
[TBL] [Abstract][Full Text] [Related]
46. [Analysis of phonosurgical methods of treatment in spasmodic dysphonia].
Kosztyła-Hojna B; Berger G; Zdrojkowski M
Pol Merkur Lekarski; 2017 Feb; 42(248):90-92. PubMed ID: 28258685
[TBL] [Abstract][Full Text] [Related]
47. Physiologic assessment of botulinum toxin effects in the rat larynx.
Inagi K; Connor NP; Ford CN; Schultz E; Rodriquez AA; Bless DM; Pasic T; Heisey DM
Laryngoscope; 1998 Jul; 108(7):1048-54. PubMed ID: 9665255
[TBL] [Abstract][Full Text] [Related]
48. The impact of long-term botulinum toxin injections on symptom severity in patients with spasmodic dysphonia.
Damrose JF; Goldman SN; Groessl EJ; Orloff LA
J Voice; 2004 Sep; 18(3):415-22. PubMed ID: 15331116
[TBL] [Abstract][Full Text] [Related]
49. Quantitative laryngeal electromyography parameters may correlate with improved outcomes following botulinum toxin injection for spasmodic dysphonia.
Dwyer CD; Leclerc AA; Nandedkar SD; Young VN; Rosen CA
Muscle Nerve; 2021 Apr; 63(4):525-530. PubMed ID: 33382480
[TBL] [Abstract][Full Text] [Related]
50. A comparison of bilateral and unilateral botulinum toxin treatments for spasmodic dysphonia.
Zwirner P; Murry T; Woodson GE
Eur Arch Otorhinolaryngol; 1993; 250(5):271-6. PubMed ID: 8217128
[TBL] [Abstract][Full Text] [Related]
51. Longitudinal effects of botulinum toxin injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia.
Hogikyan ND; Wodchis WP; Spak C; Kileny PR
J Voice; 2001 Dec; 15(4):576-86. PubMed ID: 11792036
[TBL] [Abstract][Full Text] [Related]
52. Botulinum toxin for the treatment of spasticity in multiple sclerosis. New observations.
Borg-Stein J; Pine ZM; Miller JR; Brin MF
Am J Phys Med Rehabil; 1993 Dec; 72(6):364-8. PubMed ID: 8260129
[TBL] [Abstract][Full Text] [Related]
53. Factors Associated with Failure of Botulinum Toxin Injection in Adductor Spasmodic Dysphonia.
Zhao K; Guillaud M; Hu A
Ann Otol Rhinol Laryngol; 2020 Oct; 129(10):996-1002. PubMed ID: 32468829
[TBL] [Abstract][Full Text] [Related]
54. Treatment of adductor laryngeal breathing dystonia with botulinum toxin type A.
Grillone GA; Blitzer A; Brin MF; Annino DJ; Saint-Hilaire MH
Laryngoscope; 1994 Jan; 104(1 Pt 1):30-2. PubMed ID: 8295454
[TBL] [Abstract][Full Text] [Related]
55. Refractory Dysphonia Due to Isolated Cricothyroid Muscle Dystonia.
Kraft S; Childes J; Hillel A; Schindler J
J Voice; 2016 Jul; 30(4):501-5. PubMed ID: 26239970
[TBL] [Abstract][Full Text] [Related]
56. Adductor muscle activity abnormalities in abductor spasmodic dysphonia.
Cyrus CB; Bielamowicz S; Evans FJ; Ludlow CL
Otolaryngol Head Neck Surg; 2001 Jan; 124(1):23-30. PubMed ID: 11228447
[TBL] [Abstract][Full Text] [Related]
57. Interarytenoid muscle botox injection for treatment of adductor spasmodic dysphonia with vocal tremor.
Kendall KA; Leonard RJ
J Voice; 2011 Jan; 25(1):114-9. PubMed ID: 20137891
[TBL] [Abstract][Full Text] [Related]
58. Management of supraglottic squeeze in adductor spasmodic dysphonia: a new technique.
Young N; Blitzer A
Laryngoscope; 2007 Nov; 117(11):2082-4. PubMed ID: 17828055
[TBL] [Abstract][Full Text] [Related]
59. Unilateral versus bilateral botulinum toxin injections in adductor spasmodic dysphonia.
Langeveld TP; Drost HA; Baatenburg de Jong RJ
Ann Otol Rhinol Laryngol; 1998 Apr; 107(4):280-4. PubMed ID: 9557760
[TBL] [Abstract][Full Text] [Related]
60. Anatomic considerations in botulinum toxin type A therapy for spasmodic dysphonia.
Castellanos PF; Gates GA; Esselman G; Song F; Vannier MW; Kuo M
Laryngoscope; 1994 Jun; 104(6 Pt 1):656-62. PubMed ID: 8196438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
